Literature DB >> 29512176

Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan.

Theodora Bejan-Angoulvant1, Thibaud Genet2, Laura Vrignaud3, Denis Angoulvant2, Laurent Fauchier2.   

Abstract

Entities:  

Keywords:  adverse drug reactions; drug information; drug safety; heart failure; pharmacovigilance

Mesh：

Substances：

Year:  2018        PMID： 29512176      PMCID： PMC5903246          DOI： 10.1111/bcp.13545

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

Review 1.  Updating the French method for the causality assessment of adverse drug reactions.

Authors:  Yannick Arimone; Irène Bidault; Jean-Paul Dutertre; Marie Gérardin; Claire Guy; Françoise Haramburu; Dominique Hillaire-Buys; Carmine Meglio; Catherine Penfornis; Hélène Théophile; Marie-Blanche Valnet-Rabier
Journal:  Therapie       Date:  2013-06-18       Impact factor: 2.070

2.  Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan.

Authors:  Theodora Bejan-Angoulvant; Thibaud Genet; Laura Vrignaud; Denis Angoulvant; Laurent Fauchier
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

3.  Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors.

Authors:  C Marin; T N Chase
Journal:  Neuropharmacology       Date:  1995-06       Impact factor: 5.250

Review 4.  The value of patient reporting to the pharmacovigilance system: a systematic review.

Authors:  Pedro Inácio; Afonso Cavaco; Marja Airaksinen
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

Review 5.  Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.

Authors:  Surya Ayalasomayajula; Thomas Langenickel; Parasar Pal; Sreedevi Boggarapu; Gangadhar Sunkara
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

6.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

7.  Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman.

Authors:  Eve S Faber; Madhavi Gavini; Ronald Ramirez; Richard Sadovsky
Journal:  Drug Saf Case Rep       Date:  2016-12
  7 in total
  2 in total

1.  Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan.

Authors:  Theodora Bejan-Angoulvant; Thibaud Genet; Laura Vrignaud; Denis Angoulvant; Laurent Fauchier
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

2.  WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information.

Authors:  Olof Lagerlund; Sara Strese; Malin Fladvad; Marie Lindquist
Journal:  Ther Innov Regul Sci       Date:  2020-02-20       Impact factor: 1.778
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.